Reshma Kewalramani, the Indian-origin CEO and President of Vertex Pharmaceuticals, has emerged as one of the most influential and wealthiest Indian-origin women business leaders in the world, with an estimated net worth exceeding $100 million as of mid-2025.
Who is Reshma Kewalramani?
Born in Mumbai, Reshma moved to the United States at the age of 11. She earned her medical degree from Boston University and completed medical training at top institutions including Massachusetts General Hospital and Brigham and Women’s Hospital. In 2015, she completed the General Management Program at Harvard Business School, preparing her for leadership roles in the healthcare and biotech sectors.
Reshma joined Vertex Pharmaceuticals in 2017 as Chief Medical Officer and rose to become CEO and President in April 2020. She made history as the first woman to lead a major publicly traded US biotech company. Under her leadership, Vertex has achieved several medical breakthroughs, including FDA approval of the first CRISPR-based gene editing therapies to treat sickle cell disease and beta thalassemia. The company has also continued to advance treatments for cystic fibrosis and is working on opioid-free pain medications.
What is Reshma Kewalramani’s net worth?
As of mid-2025, Dr. Kewalramani’s net worth is estimated to range between $100 million and $103 million. This includes her ownership of approximately 105,915 shares of Vertex stock, currently valued at around $47.5 million. She has also earned roughly $53.6 million through stock sales since 2021. In 2024 alone, her compensation package as CEO,comprising salary, bonuses, and stock options, was valued at $21.5 million.
While a portion of her wealth also comes from directorship roles such as with Ginkgo Bioworks, the bulk of her fortune is tied to her leadership at Vertex. Her accomplishments have earned her a spot on TIME magazine’s 2025 list of the “100 Most Influential People,” cementing her position as a global icon in the biotech industry.